CR20110440A - Compuestos de piridazinona - Google Patents
Compuestos de piridazinonaInfo
- Publication number
- CR20110440A CR20110440A CR20110440A CR20110440A CR20110440A CR 20110440 A CR20110440 A CR 20110440A CR 20110440 A CR20110440 A CR 20110440A CR 20110440 A CR20110440 A CR 20110440A CR 20110440 A CR20110440 A CR 20110440A
- Authority
- CR
- Costa Rica
- Prior art keywords
- piridazinona
- compounds
- medicament
- useful
- preventing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invención provee un compuesto que tiene el efecto de inhibir la PDE inhibition, y que es útil como un medicamento para prevenir o tratar la esquizofrenia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20220709P | 2009-02-05 | 2009-02-05 | |
| US21392709P | 2009-07-30 | 2009-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20110440A true CR20110440A (es) | 2012-02-13 |
Family
ID=42398214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20110440A CR20110440A (es) | 2009-02-05 | 2011-08-17 | Compuestos de piridazinona |
Country Status (38)
| Country | Link |
|---|---|
| US (7) | US8354411B2 (es) |
| EP (2) | EP3006031A1 (es) |
| JP (1) | JP5659166B2 (es) |
| KR (1) | KR101730665B1 (es) |
| CN (1) | CN102365020B (es) |
| AR (1) | AR075238A1 (es) |
| AU (1) | AU2010211050B2 (es) |
| BR (1) | BRPI1008498B8 (es) |
| CA (1) | CA2751565C (es) |
| CO (1) | CO6410258A2 (es) |
| CR (1) | CR20110440A (es) |
| DK (1) | DK2393360T3 (es) |
| DO (1) | DOP2011000254A (es) |
| EA (1) | EA020690B1 (es) |
| EC (1) | ECSP11011305A (es) |
| ES (1) | ES2561181T3 (es) |
| GE (1) | GEP20146004B (es) |
| HK (1) | HK1164642A1 (es) |
| HR (1) | HRP20160065T1 (es) |
| HU (1) | HUE027478T2 (es) |
| IL (1) | IL214137A (es) |
| JO (1) | JO3114B1 (es) |
| MA (1) | MA33072B1 (es) |
| ME (1) | ME02337B (es) |
| MX (1) | MX2011008305A (es) |
| MY (1) | MY170610A (es) |
| NZ (1) | NZ594851A (es) |
| PE (1) | PE20110991A1 (es) |
| PL (1) | PL2393360T3 (es) |
| RS (1) | RS54504B1 (es) |
| SG (1) | SG173175A1 (es) |
| SI (1) | SI2393360T1 (es) |
| SM (1) | SMT201600008B (es) |
| TN (1) | TN2011000362A1 (es) |
| TW (1) | TWI457333B (es) |
| UY (1) | UY32417A (es) |
| WO (1) | WO2010090737A1 (es) |
| ZA (1) | ZA201106074B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200924774A (en) * | 2007-10-26 | 2009-06-16 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5 |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| EP3006031A1 (en) | 2009-02-05 | 2016-04-13 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
| MY165585A (en) | 2010-06-24 | 2018-04-05 | Takeda Pharmaceuticals Co | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| US20130116231A1 (en) * | 2010-07-12 | 2013-05-09 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| JP5800813B2 (ja) * | 2010-08-04 | 2015-10-28 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2012018058A1 (ja) | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP5760085B2 (ja) | 2010-08-04 | 2015-08-05 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US9150588B2 (en) | 2010-08-10 | 2015-10-06 | Takeda Pharmaceutical Company Limited | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors |
| JP2013234123A (ja) * | 2010-09-03 | 2013-11-21 | Taisho Pharmaceutical Co Ltd | ３−ピラゾリル−２−ピリドン誘導体 |
| US8772316B2 (en) | 2011-02-18 | 2014-07-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
| US9029388B2 (en) | 2011-03-16 | 2015-05-12 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US9579407B2 (en) | 2011-08-22 | 2017-02-28 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (PDE10A) in mammals |
| US9212147B2 (en) | 2011-11-15 | 2015-12-15 | Takeda Pharmaceutical Company Limited | Dihydroxy aromatic heterocyclic compound |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| MA38427A1 (fr) | 2013-02-21 | 2018-08-31 | Takeda Pharmaceuticals Co | Procédé de production d'un composé de pyridazinone |
| JPWO2014142322A1 (ja) | 2013-03-15 | 2017-02-16 | 第一三共株式会社 | ベンゾチオフェン誘導体 |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| MX370085B (es) * | 2013-09-12 | 2019-11-29 | Janssen Biopharma Inc | Compuestos de piridazinona y usos de los mismos. |
| CA2923075C (en) | 2013-09-12 | 2022-07-26 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| ES2544869B2 (es) * | 2014-03-04 | 2016-01-18 | Universidade De Vigo | Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa |
| EP3120871B1 (en) * | 2014-03-18 | 2023-06-28 | Takeda Pharmaceutical Company Limited | Solid dispersion |
| WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| EA036776B1 (ru) | 2015-03-11 | 2020-12-21 | Янссен Байофарма, Инк. | Соединения азапиридона и способы их применения |
| WO2016191935A1 (en) * | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| CN107428721B (zh) | 2015-12-22 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物、其制备方法及其在医药上的应用 |
| US10736894B2 (en) | 2018-02-15 | 2020-08-11 | Ovid Therapeutics Inc. | Methods of treating developmental syndromes with PDE10A inhibitors |
| CN108498868B (zh) * | 2018-04-03 | 2020-09-15 | 北京大学口腔医学院 | 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法 |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| WO2019241787A1 (en) * | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use |
| EP3856185A1 (en) * | 2018-09-28 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| MX2019008440A (es) | 2019-07-15 | 2021-01-18 | Dva Farma Mexicana S A De C V | Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion. |
| GB202002926D0 (en) | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011693A1 (de) | 1978-10-03 | 1980-06-11 | Ciba-Geigy Ag | Neue N-(trifluormethansulfonylaminophenyl)-substituierte N-Heterocyclen, ihre Herstellung, sie enthaltende Mittel und ihre Verwendung zur Beeinflussung des Pflanzenwachstums |
| FR2648135B1 (fr) * | 1989-06-07 | 1991-09-27 | Pf Medicament | Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique |
| GB9506382D0 (en) * | 1995-03-29 | 1995-05-17 | Boots Co Plc | Pharmaceutical compositions |
| WO2000009488A1 (fr) | 1998-08-14 | 2000-02-24 | Nihon Nohyaku Co., Ltd. | Derives de pyridazinone |
| US20070060606A1 (en) * | 1999-10-07 | 2007-03-15 | Robertson Harold A | Compounds and methods for modulating phosphodiesterase 10A |
| GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| CA2422371C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| MXPA06014236A (es) | 2004-06-07 | 2007-02-14 | Pfizer Prod Inc | Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad. |
| WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
| EP1841757B1 (en) | 2005-01-07 | 2010-06-30 | Pfizer Products Incorporated | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
| US7763617B2 (en) | 2005-03-07 | 2010-07-27 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient |
| WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
| WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
| AR074343A1 (es) | 2008-11-14 | 2011-01-12 | Amgen Inc | Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10 |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| CA2744489C (en) * | 2008-12-04 | 2015-06-23 | F.Hoffmann-La Roche Ag | Pyridazinone derivatives |
| EP3006031A1 (en) | 2009-02-05 | 2016-04-13 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
| US9187455B2 (en) | 2009-02-23 | 2015-11-17 | Hoffmann-La Roche Inc. | Substituted pyridazines as PDE10A inhibitors |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| WO2012018058A1 (ja) * | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US9150588B2 (en) * | 2010-08-10 | 2015-10-06 | Takeda Pharmaceutical Company Limited | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors |
-
2010
- 2010-02-04 EP EP15192646.6A patent/EP3006031A1/en not_active Withdrawn
- 2010-02-04 SG SG2011054491A patent/SG173175A1/en unknown
- 2010-02-04 WO PCT/US2010/000307 patent/WO2010090737A1/en active Application Filing
- 2010-02-04 ME MEP-2016-194A patent/ME02337B/me unknown
- 2010-02-04 SI SI201031103T patent/SI2393360T1/sl unknown
- 2010-02-04 MA MA34133A patent/MA33072B1/fr unknown
- 2010-02-04 HU HUE10738857A patent/HUE027478T2/en unknown
- 2010-02-04 US US13/148,172 patent/US8354411B2/en active Active
- 2010-02-04 JO JOP/2010/0038A patent/JO3114B1/ar active
- 2010-02-04 ES ES10738857.1T patent/ES2561181T3/es active Active
- 2010-02-04 EP EP10738857.1A patent/EP2393360B1/en active Active
- 2010-02-04 US US12/656,605 patent/US8916566B2/en active Active
- 2010-02-04 TW TW099103286A patent/TWI457333B/zh active
- 2010-02-04 CN CN201080014965.6A patent/CN102365020B/zh active Active
- 2010-02-04 KR KR1020117020556A patent/KR101730665B1/ko active IP Right Grant
- 2010-02-04 UY UY0001032417A patent/UY32417A/es not_active Application Discontinuation
- 2010-02-04 JP JP2011549157A patent/JP5659166B2/ja active Active
- 2010-02-04 EA EA201171004A patent/EA020690B1/ru not_active IP Right Cessation
- 2010-02-04 PE PE2011001434A patent/PE20110991A1/es active IP Right Grant
- 2010-02-04 BR BRPI1008498A patent/BRPI1008498B8/pt active IP Right Grant
- 2010-02-04 NZ NZ594851A patent/NZ594851A/xx unknown
- 2010-02-04 GE GEAP201012363A patent/GEP20146004B/en unknown
- 2010-02-04 AU AU2010211050A patent/AU2010211050B2/en active Active
- 2010-02-04 CA CA2751565A patent/CA2751565C/en active Active
- 2010-02-04 AR ARP100100304A patent/AR075238A1/es active IP Right Grant
- 2010-02-04 MX MX2011008305A patent/MX2011008305A/es active IP Right Grant
- 2010-02-04 MY MYPI2011003610A patent/MY170610A/en unknown
- 2010-02-04 RS RS20150859A patent/RS54504B1/en unknown
- 2010-02-04 DK DK10738857.1T patent/DK2393360T3/en active
- 2010-02-04 PL PL10738857T patent/PL2393360T3/pl unknown
-
2011
- 2011-07-18 IL IL214137A patent/IL214137A/en active IP Right Grant
- 2011-07-22 TN TN2011000362A patent/TN2011000362A1/fr unknown
- 2011-08-03 DO DO2011000254A patent/DOP2011000254A/es unknown
- 2011-08-17 CR CR20110440A patent/CR20110440A/es unknown
- 2011-08-18 ZA ZA2011/06074A patent/ZA201106074B/en unknown
- 2011-08-23 CO CO11106877A patent/CO6410258A2/es active IP Right Grant
- 2011-09-05 EC EC2011011305A patent/ECSP11011305A/es unknown
-
2012
- 2012-05-30 HK HK12105294.8A patent/HK1164642A1/zh unknown
- 2012-07-06 US US13/543,207 patent/US8778944B2/en active Active
- 2012-07-06 US US13/543,332 patent/US8435995B2/en active Active
- 2012-07-06 US US13/543,296 patent/US8513251B2/en active Active
-
2014
- 2014-10-17 US US14/517,313 patent/US9550756B2/en active Active
-
2016
- 2016-01-08 SM SM201600008T patent/SMT201600008B/it unknown
- 2016-01-20 HR HRP20160065TT patent/HRP20160065T1/hr unknown
- 2016-12-13 US US15/377,149 patent/US20170114044A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20110440A (es) | Compuestos de piridazinona | |
| CR20130024A (es) | Compuestos heterocíclicos fusionados | |
| CR20130281A (es) | Compuesto bicíclico | |
| SV2009003307A (es) | Quinazolinas para la inhibicion de pdk1 | |
| GT201200220A (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
| BR112016014412A2 (pt) | Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo | |
| CR20120659A (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer | |
| BRPI0710521A2 (pt) | quinazolinas para inibição de pdk1 | |
| CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
| ECSP14013236A (es) | Polimorfos de inhibidores de cinasas | |
| MX2016008688A (es) | Compuestos terapéuticos inhibidores. | |
| MX2012006913A (es) | Profarmacos de inhibidores de calicreina plasmatica. | |
| CR20110492A (es) | Compuestos tetracíclicos | |
| SV2009003373A (es) | COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759 | |
| CR20140036A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CO6300951A2 (es) | Derivados de azaciclilisoquinolinona e- isoindolinona como antagonistas de la histamina-3 | |
| CO6300955A2 (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina -3 | |
| CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
| BR112012023836A2 (pt) | composto tricíclicos e inibidores de pbk contendo os mesmos | |
| UY33701A (es) | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina | |
| BR112017005113A2 (pt) | composto de fórmula geral (i), método para preparar um composto de fórmula geral (i), método para preparar um composto de fórmula geral (iv), composição farmacêutica para o tratamento de doenças relacionadas com atividades anormais de jak3 e/ou jak1 quinase, usos do composto, e usos da composição farmacêutica | |
| BR112013033836A2 (pt) | terapia de combinação | |
| CL2012001758A1 (es) | Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas. | |
| CL2011001850A1 (es) | Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. |